Sodium-glucose co-transporter-2 (SGLT-2) inhibitors and uric acid: More good news!

Competing Interests: Declaration of competing interest NK has given talks, attended conferences and participated in trials sponsored by Amgen, Astra Zeneca, Boehringer Ingelheim, Elpen, Libytec, Novartis, Novo Nordisk, Sanofi and Viatris. DPM has given talks, acted as a consultant or attended conferences sponsored by Amgen and Novo Nordisk. MR has given lectures, received honoraria and research support, and participated in conferences, advisory boards, and clinical trials sponsored by many pharmaceutical companies including Amgen, Astra Zeneca, Boehringer Ingelheim, Kowa, Eli Lilly, Meda, Mylan, Merck Sharp & Dohme, Novo Nordisk, Novartis, Roche Diagnostics, Sanofi, and Servier. None of the above-mentioned pharmaceutical companies had any role in this article, which has been written independently, without any financial or professional help, and reflects only the opinion of the authors, without any role of the industry.